Katie L. Stone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Katie L. Stone has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Brian E. Cade
Brigham and Women's Hospital
2 shared publications - David R. Hillman
West Australian Sleep Disorders Research Institute, Centre for Sleep Science, University of Western Australia, Perth, Australia
2 shared publications - Gregory J. Tranah
California Pacific Medical Center Research Institute
2 shared publications - Heming Wang
Brigham and Women's Hospital, Harvard Medical School
2 shared publications - Jane A. Cauley
Department of Epidemiology, School of Public Health, University of Pittsburgh , Pittsburgh, PA 15261
2 shared publications - Jerome I. Rotter
The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA USA
2 shared publications
Latest Publications
- Open Access
Leveraging pleiotropy to discover and interpret GWAS results for sleep-associated traits
Genetic association studies of many heritable traits resulting from physiological testing often have modest sample sizes due to the cost and burden of the required phenotyping. This reduces statistical power and limits discovery of multiple genetic associations. We present a strategy to leverage pleiotropy between traits to both discover new loci and to provide mechanistic hypotheses of the underlying pathophysiology. Specifically, we combine a colocalization test with a locus-level test of pleiotropy. In simulations, we show that this approach is highly selective for identifying true pleiotropy driven by the same causative variant, thereby improves the chance to replicate the associations in underpowered validation cohorts and leads to higher interpretability. Here, as an exemplar, we use Obstructive Sleep Apnea (OSA), a common disorder diagnosed using overnight multi-channel physiological testing. We leverage pleiotropy with relevant cellular and cardio-metabolic phenotypes and gene expression traits to map new risk loci in an underpowered OSA GWAS. We identify several pleiotropic loci harboring suggestive associations to OSA and genome-wide significant associations to other traits, and show that their OSA association replicates in independent cohorts of diverse ancestries. By investigating pleiotropic loci, our strategy allows proposing new hypotheses about OSA pathobiology across many physiological layers. For example, we identify and replicate the pleiotropy across the plateletcrit, OSA and an eQTL of DNA primase subunit 1 ( PRIM1 ) in immune cells. We find suggestive links between OSA, a measure of lung function (FEV 1 /FVC), and an eQTL of matrix metallopeptidase 15 ( MMP15 ) in lung tissue. We also link a previously known genome-wide significant peak for OSA in the hexokinase 1 ( HK1 ) locus to hematocrit and other red blood cell related traits. Thus, the analysis of pleiotropic associations has the potential to assemble diverse phenotypes into a chain of mechanistic hypotheses that provide insight into the pathogenesis of complex human diseases. Author Summary: Large genetic studies with hundreds of thousands of patients have been successful at finding genetic variants that associate with disease traits in humans. However, smaller-scale studies can often have inadequate power to discover new genetic associations. Here, we use a small genetic study of Obstructive Sleep Apnea (OSA), to introduce a strategy that both helps find genetic associations and proposes biological hypotheses for the mechanisms behind those associations. To achieve this, we use large genetic studies carried out on traits that are related to OSA, and look for genetic variants that affect both OSA in our small study and the trait in question in the large study. By linking two or more traits at select loci, we were able to, among other results, find a locus that affects the expression of a gene in immune cells (DNA primase subunit 1), a marker of thrombotic and inflammatory processes (plateletcrit) and OSA. This results in a novel genetic association to OSA and a corresponding biological hypothesis behind its effect on OSA.
Open AccessLeveraging pleiotropy to discover and interpret GWAS results for sleep-associated traits
Genetic association studies of many heritable traits resulting from physiological testing often have modest sample sizes due to the cost and burden of the required phenotyping. This reduces statistical power and limits discovery of multiple genetic associations. We present a strategy to leverage pleiotropy between traits to both discover new loci and to provide mechanistic hypotheses of the underlying pathophysiology. Specifically, we combine a colocalization test with a locus-level test of pleiotropy. In simulations, we show that this approach is highly selective for identifying true pleiotropy driven by the same causative variant, thereby improves the chance to replicate the associations in underpowered validation cohorts and leads to higher interpretability. Here, as an exemplar, we use Obstructive Sleep Apnea (OSA), a common disorder diagnosed using overnight multi-channel physiological testing. We leverage pleiotropy with relevant cellular and cardio-metabolic phenotypes and gene expression traits to map new risk loci in an underpowered OSA GWAS. We identify several pleiotropic loci harboring suggestive associations to OSA and genome-wide significant associations to other traits, and show that their OSA association replicates in independent cohorts of diverse ancestries. By investigating pleiotropic loci, our strategy allows proposing new hypotheses about OSA pathobiology across many physiological layers. For example, we identify and replicate the pleiotropy across the plateletcrit, OSA and an eQTL of DNA primase subunit 1 ( PRIM1 ) in immune cells. We find suggestive links between OSA, a measure of lung function (FEV 1 /FVC), and an eQTL of matrix metallopeptidase 15 ( MMP15 ) in lung tissue. We also link a previously known genome-wide significant peak for OSA in the hexokinase 1 ( HK1 ) locus to hematocrit and other red blood cell related traits. Thus, the analysis of pleiotropic associations has the potential to assemble diverse phenotypes into a chain of mechanistic hypotheses that provide insight into the pathogenesis of complex human diseases. Author Summary: Large genetic studies with hundreds of thousands of patients have been successful at finding genetic variants that associate with disease traits in humans. However, smaller-scale studies can often have inadequate power to discover new genetic associations. Here, we use a small genetic study of Obstructive Sleep Apnea (OSA), to introduce a strategy that both helps find genetic associations and proposes biological hypotheses for the mechanisms behind those associations. To achieve this, we use large genetic studies carried out on traits that are related to OSA, and look for genetic variants that affect both OSA in our small study and the trait in question in the large study. By linking two or more traits at select loci, we were able to, among other results, find a locus that affects the expression of a gene in immune cells (DNA primase subunit 1), a marker of thrombotic and inflammatory processes (plateletcrit) and OSA. This results in a novel genetic association to OSA and a corresponding biological hypothesis behind its effect on OSA.
- Open Access
Whole-Genome Association Analyses of Sleep-disordered Breathing Phenotypes in the NHLBI TOPMed Program
Sleep-disordered breathing (SDB) is a common disorder associated with significant morbidity. Through the NHLBI Trans-Omics for Precision Medicine (TOPMed) program we report the first whole-genome sequence analysis of SDB. We identified 4 rare gene-based associations with SDB traits in 7,988 individuals of diverse ancestry and 4 replicated common variant associations with inclusion of additional samples (n=13,257). We identified a multi-ethnic set-based rare-variant association (p = 3.48 × 10 −8 ) on chromosome X with ARMCX3 . Transcription factor binding site enrichment identified associations with genes implicated with respiratory and craniofacial traits. Results highlighted associations in genes that modulate lung development, inflammation, respiratory rhythmogenesis and HIF1A -mediated hypoxic response.
Open AccessWhole-Genome Association Analyses of Sleep-disordered Breathing Phenotypes in the NHLBI TOPMed Program
Sleep-disordered breathing (SDB) is a common disorder associated with significant morbidity. Through the NHLBI Trans-Omics for Precision Medicine (TOPMed) program we report the first whole-genome sequence analysis of SDB. We identified 4 rare gene-based associations with SDB traits in 7,988 individuals of diverse ancestry and 4 replicated common variant associations with inclusion of additional samples (n=13,257). We identified a multi-ethnic set-based rare-variant association (p = 3.48 × 10 −8 ) on chromosome X with ARMCX3 . Transcription factor binding site enrichment identified associations with genes implicated with respiratory and craniofacial traits. Results highlighted associations in genes that modulate lung development, inflammation, respiratory rhythmogenesis and HIF1A -mediated hypoxic response.
- 1 September 2018
- Published by Elsevier in Sleep Medicine Clinics
- Vol. 13 (3) , 457-465
Impact of Poor Sleep on Physical and Mental Health in Older Women
- 1 September 2018
- Published by Elsevier in Sleep Medicine Clinics
- Vol. 13 (3) , 457-465
Impact of Poor Sleep on Physical and Mental Health in Older Women
- Open Access
- 1 December 2017
- Published by Elsevier in Bone Reports
- Vol. 7, 156-163
Rest-activity circadian rhythms and bone mineral density in elderly men
- 1 December 2017
- Published by Elsevier in Bone Reports
- Vol. 7, 156-163
Open AccessRest-activity circadian rhythms and bone mineral density in elderly men
- 25 October 2017
- Published by Springer Nature
- p. 305-321
Circadian Sleep-Wake Activity Patterns During Aging
- 25 October 2017
- Published by Springer Nature
- p. 305-321
Circadian Sleep-Wake Activity Patterns During Aging
- Open Access
- 29 July 2017
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 32 (12) , 2331-2338
Effect of Combination Folic Acid, Vitamin B6, and Vitamin B12 Supplementation on Fracture Risk in Women: A Randomized, Controlled Trial
Epidemiologic studies have demonstrated an association of elevated plasma homocysteine levels with greater bone resorption and fracture risk. Vitamins B12, B6, and folic acid are cofactors in homocysteine metabolism, and supplementation with B vitamins is effective in lowering homocysteine levels in humans. However, randomized trials of supplemental B vitamins for reduction of fracture risk have been limited. Therefore, we performed an ancillary study to the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS), a large randomized trial of women with preexisting cardiovascular disease or three or more coronary risk factors, to test whether a daily B vitamin intervention including folic acid (2.5 mg/day), vitamin B6 (50 mg/day), and vitamin B12 (1 mg/day) reduces nonspine fracture risk over 7.3 years of treatment and follow‐up. Among 4810 women, we confirmed 349 nonspine fracture cases by centralized review of medical records. In a substudy of 300 women (150 in treatment group and 150 controls) with paired plasma samples at randomization and follow‐up (7.3 years later), we measured two bone turnover markers, including C‐terminal cross‐linking telopeptide of type I collagen (CTX) and intact type I procollagen N‐propeptide (P1NP). In Cox proportional hazards models based on intention‐to‐treat, we found no significant effects of B vitamin supplementation on nonspine fracture risk (relative hazard = 1.08; 95% confidence interval, 0.88 to 1.34). In a nested case‐cohort analysis, there were no significant effects of B vitamins on fracture risk among women with elevated plasma homocysteine levels, or low levels of vitamins B12 or B6, or folate at baseline. Furthermore, treatment with B vitamins had no effect on change in markers of bone turnover. We found no evidence that daily supplementation with B vitamins reduces fracture risk or rates of bone metabolism in middle‐aged and older women at high risk of cardiovascular disease. © 2017 American Society for Bone and Mineral Research.
- 29 July 2017
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 32 (12) , 2331-2338
Open AccessEffect of Combination Folic Acid, Vitamin B6, and Vitamin B12 Supplementation on Fracture Risk in Women: A Randomized, Controlled Trial
Epidemiologic studies have demonstrated an association of elevated plasma homocysteine levels with greater bone resorption and fracture risk. Vitamins B12, B6, and folic acid are cofactors in homocysteine metabolism, and supplementation with B vitamins is effective in lowering homocysteine levels in humans. However, randomized trials of supplemental B vitamins for reduction of fracture risk have been limited. Therefore, we performed an ancillary study to the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS), a large randomized trial of women with preexisting cardiovascular disease or three or more coronary risk factors, to test whether a daily B vitamin intervention including folic acid (2.5 mg/day), vitamin B6 (50 mg/day), and vitamin B12 (1 mg/day) reduces nonspine fracture risk over 7.3 years of treatment and follow‐up. Among 4810 women, we confirmed 349 nonspine fracture cases by centralized review of medical records. In a substudy of 300 women (150 in treatment group and 150 controls) with paired plasma samples at randomization and follow‐up (7.3 years later), we measured two bone turnover markers, including C‐terminal cross‐linking telopeptide of type I collagen (CTX) and intact type I procollagen N‐propeptide (P1NP). In Cox proportional hazards models based on intention‐to‐treat, we found no significant effects of B vitamin supplementation on nonspine fracture risk (relative hazard = 1.08; 95% confidence interval, 0.88 to 1.34). In a nested case‐cohort analysis, there were no significant effects of B vitamins on fracture risk among women with elevated plasma homocysteine levels, or low levels of vitamins B12 or B6, or folate at baseline. Furthermore, treatment with B vitamins had no effect on change in markers of bone turnover. We found no evidence that daily supplementation with B vitamins reduces fracture risk or rates of bone metabolism in middle‐aged and older women at high risk of cardiovascular disease. © 2017 American Society for Bone and Mineral Research.
- 1 March 2004
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 89 (3) , 1217-1221
Low Serum Vitamin B-12 Levels Are Associated with Increased Hip Bone Loss in Older Women: A Prospective Study
The purpose of this study was to test whether low serum vitamin B-12 levels are associated with more rapid bone loss in elderly women. We archived sera and measured calcaneal bone mineral density (BMD) in community-dwelling white women, aged 65 yr and over, who participated in the Study of Osteoporotic Fractures. BMD of the hip and subregions was measured 2 yr later. Repeat measurements of calcaneal and hip BMD were obtained after 5.9 and 3.5 yr of follow-up, respectively. Serum vitamin B-12 assays were performed in 83 randomly selected participants with initial and repeat measurements of BMD who were not taking estrogen replacement therapy at baseline. After adjusting for age, weight, and clinic site, women with vitamin B-12 levels at or below 280 pg/ml (207.2 pmol/liter; lowest quintile) experienced an annual change of -1.6% (95% confidence interval, -2.4% to -0.8%) in total hip BMD, compared with -0.2% (-0.5% to 0.2%) in women with levels above 280 pg/ml (P = 0.003). Results were similar when subregions of the hip were analyzed separately. Serum vitamin B-12 levels were not significantly associated with calcaneal bone loss. We conclude that low serum vitamin B-12 levels are associated with increased rates of hip, but not calcaneal, bone loss in older women.
- 1 March 2004
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 89 (3) , 1217-1221
Low Serum Vitamin B-12 Levels Are Associated with Increased Hip Bone Loss in Older Women: A Prospective Study
The purpose of this study was to test whether low serum vitamin B-12 levels are associated with more rapid bone loss in elderly women. We archived sera and measured calcaneal bone mineral density (BMD) in community-dwelling white women, aged 65 yr and over, who participated in the Study of Osteoporotic Fractures. BMD of the hip and subregions was measured 2 yr later. Repeat measurements of calcaneal and hip BMD were obtained after 5.9 and 3.5 yr of follow-up, respectively. Serum vitamin B-12 assays were performed in 83 randomly selected participants with initial and repeat measurements of BMD who were not taking estrogen replacement therapy at baseline. After adjusting for age, weight, and clinic site, women with vitamin B-12 levels at or below 280 pg/ml (207.2 pmol/liter; lowest quintile) experienced an annual change of -1.6% (95% confidence interval, -2.4% to -0.8%) in total hip BMD, compared with -0.2% (-0.5% to 0.2%) in women with levels above 280 pg/ml (P = 0.003). Results were similar when subregions of the hip were analyzed separately. Serum vitamin B-12 levels were not significantly associated with calcaneal bone loss. We conclude that low serum vitamin B-12 levels are associated with increased rates of hip, but not calcaneal, bone loss in older women.
- Top Cited PapersOpen Access
- 1 November 2003
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 18 (11) , 1947-1954
BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long-Term Results From the Study of Osteoporotic Fractures
In a large cohort of U.S. women aged 65 and older, we report the relationships of BMD measured at several sites, and subsequent fracture risk at multiple sites over >8 years of follow-up. Although we found almost all fracture types to be related to low BMD, the overall proportion of fractures attributable to low BMD is modest. Introduction: Although several studies have reported the relationship between bone mineral density (BMD) and subsequent fracture risk, most have been limited by short follow-up time, BMD measures at only one or two sites, or availability of data for only select fracture types. Materials and Methods: In the multicenter Study of Osteoporotic Fractures (SOF), we studied the relationship of several different BMD measures to fracture risk of multiple types in 9704 non-black women aged 65 and older. We previously reported on the relationship of peripheral BMD measures to risk of several types of fracture during an average 2.2-year follow-up period. In this expanded analysis, we present results of the relationship of both peripheral and central BMD measures and fractures of multiple types during 10.4 and 8.5 years of follow-up, respectively. We also report population attributable risk (PAR) estimates for osteoporosis and risk of several types of fracture. Results: Our results show that almost all types of fractures have an increased incidence in women with low BMD. However, hip BMD is somewhat more strongly related to most of the fracture types studied than spine or peripheral BMD measures. Nonetheless, the proportion of fractures attributable to osteoporosis (based on a standard definition of osteoporosis) is modest, ranging from <10% to 44% based on the most commonly used definition of osteoporosis (BMD T-score < −2.5). Conclusion: Finding effective prevention strategies for fractures in older women will require additional interventions beside preventions for bone loss, such as prevention of falls and other fracture risk factors.
- 1 November 2003
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 18 (11) , 1947-1954
Top Cited PapersOpen AccessBMD at Multiple Sites and Risk of Fracture of Multiple Types: Long-Term Results From the Study of Osteoporotic Fractures
In a large cohort of U.S. women aged 65 and older, we report the relationships of BMD measured at several sites, and subsequent fracture risk at multiple sites over >8 years of follow-up. Although we found almost all fracture types to be related to low BMD, the overall proportion of fractures attributable to low BMD is modest. Introduction: Although several studies have reported the relationship between bone mineral density (BMD) and subsequent fracture risk, most have been limited by short follow-up time, BMD measures at only one or two sites, or availability of data for only select fracture types. Materials and Methods: In the multicenter Study of Osteoporotic Fractures (SOF), we studied the relationship of several different BMD measures to fracture risk of multiple types in 9704 non-black women aged 65 and older. We previously reported on the relationship of peripheral BMD measures to risk of several types of fracture during an average 2.2-year follow-up period. In this expanded analysis, we present results of the relationship of both peripheral and central BMD measures and fractures of multiple types during 10.4 and 8.5 years of follow-up, respectively. We also report population attributable risk (PAR) estimates for osteoporosis and risk of several types of fracture. Results: Our results show that almost all types of fractures have an increased incidence in women with low BMD. However, hip BMD is somewhat more strongly related to most of the fracture types studied than spine or peripheral BMD measures. Nonetheless, the proportion of fractures attributable to osteoporosis (based on a standard definition of osteoporosis) is modest, ranging from <10% to 44% based on the most commonly used definition of osteoporosis (BMD T-score < −2.5). Conclusion: Finding effective prevention strategies for fractures in older women will require additional interventions beside preventions for bone loss, such as prevention of falls and other fracture risk factors.